Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMD Serono, Canadaan Affiliate of Merck KGaA, and Tercica, a subsidiary of the Ipsen Group, have entered into a five year agreement for the exclusive distribution and promotion by EMD Serono of Ipsen's Somatuline Autogel for the treatment of acromegaly in Canada.
Subscribe to our email newsletter
Under the terms of the agreement, EMD Serono will be responsible for promotion, distribution, and patient support services and Ipsen will retain ownership of the product.
The agreement is for Somatuline Autogel, which was approved by Health Canada in July 2006 and to date has been promoted and distributed by Tercica.
EMD Serono president Deborah Brown said that they are very excited to work with Ipsen to expand patient access to Somatuline Autogel in Canada, not only through distribution and healthcare provider support and education but, more importantly, through the provision of comprehensive patient support services, which can further enhance the patient experience with this therapy.